ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

被引:0
|
作者
Harbeck, Nadia [1 ]
Rack, Brigitte [1 ]
Janni, Wolfgang [1 ]
机构
[1] Univ Frauenklin Maistrasse LMU, Munich, Germany
关键词
ASCO; breast cancer; Lapatinib; taxanes; trastuzumab;
D O I
10.1159/000106770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 43rd ASCO Annual Meeting took place from June 1-5, 2007 at McCormick Place in Chicago, IL, USA. This year's meeting had the special theme of 'Translating Research into Practice', particularly featuring 445 abstracts on translational research in addition to approximately 2,000 abstracts presented on subjects like surgery, radiation therapy, chemotherapy, endocrine therapy, and targeted therapies. This short summary will focus on the two important breast cancer oral presentation sessions only, and will try to comment on the presented data with regard to their immediate impact on clinical practice. Many more research results regarding breast cancer were presented (all presentations will be available to the public from September 1, 2007 at wwwasco.org). In general, breast cancer data presented at this year's ASCO Annual Meeting confirmed current standards, and introduced promising new substances which may soon enter clinical practice. The 44th ASCO Annual Meeting will again be held in Chicago from May 30 to June 3, 2008. Those who do not want to wait another year may visit ASCO's first special Breast Cancer Symposium taking place September 7-8, 2007 in San Francisco, CA, USA. Whether this meeting will start a new tradition of a specialized ASCO breast cancer symposium, and how this development will eventually will impact on the regular San Antonio Breast Cancer Symposium in December, only time will tell.
引用
收藏
页码:241 / 243
页数:3
相关论文
共 50 条
  • [1] Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
    Sonnenblick, Amir
    Fumagalli, Debora
    Sotiriou, Christos
    Piccart, Martine
    CANCER TREATMENT REVIEWS, 2014, 40 (09) : 1089 - 1095
  • [2] Targeted therapy in breast cancer: what's new?
    Fang, Lei
    Barekati, Zeinab
    Zhang, Bei
    Liu, Zhiyong
    Zhong, Xiaoyan
    SWISS MEDICAL WEEKLY, 2011, 141
  • [3] Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer
    Chao Y.L.
    Anders C.K.
    Current Breast Cancer Reports, 2017, 9 (4) : 217 - 226
  • [4] Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain:MDAnderson Cancer Center experience
    Gao, Chao
    Wang, Fuchenchu
    Suki, Dima
    Strom, Eric
    Li, Jing
    Sawaya, Raymond
    Hsu, Limin
    Raghavendra, Akshara
    Tripathy, Debu
    Ibrahim, Nuhad K.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (04) : 961 - 970
  • [5] Standards in adjuvant systemic therapy of breast cancer
    Reinisch, Dr. M.
    Kuemmel, S.
    ONKOLOGE, 2015, 21 (11): : 1085 - 1094
  • [6] Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer The best of ASCO 2019
    Suppan, Christoph
    Balic, Marija
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) : 312 - 314
  • [7] Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer
    Pu, Xiaohong
    Shi, Jiong
    Li, Zhiwen
    Feng, Anning
    Ye, Qing
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (06) : 421 - 425
  • [8] Novel therapies in breast cancer: what is new from ASCO 2008
    David Chu
    Janice Lu
    Journal of Hematology & Oncology, 1
  • [9] Cardiovascular toxicities from systemic breast cancer therapy
    Guo, Shuang
    Wong, Serena
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [10] New options in systemic adjuvant therapy of breast cancer
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2007, 3 (01): : 8 - 15